A recent clinical trial revealed that combined cetuximab (EGFR-targeting) and dasatinib treatment for recurrent/metastatic HNSCC patients showed promising clinical benefits of improved OS from patients with low serum IL-6 level [77], suggesting that dual targeting of Src-EGFR could overcome drug resistance developed from cetuximab treatments. This evidence concerns the gene SRC and head and neck squamous cell carcinoma.